Literature DB >> 20861743

High CD4(+) T-cell surface CXCR4 density as a risk factor for R5 to X4 switch in the course of HIV-1 infection.

Anne-Laure Fiser1, Thierry Vincent, Natalie Brieu, Yea-Lih Lin, Pierre Portalès, Clément Mettling, Jacques Reynes, Pierre Corbeau.   

Abstract

For unclear reasons, about 50% of HIV-infected subjects harbour CXCR4-using (X4) viral strains in addition of CCR5-using (R5) viral strains at late stages of the disease. One hypothesis is that a low CD4(+) T-cell surface CCR5 density could facilitate the emergence of X4 strains. Alternatively, one could argue that a high CD4(+) T-cell surface CXCR4 density that is observed in individuals presenting with X4 strains, could favour R5 to X4 switch. Here, we tested both hypotheses. In vivo, we observed by quantitative flow cytometry no difference in CD4(+) T-cell surface CCR5 densities between patients with or without X4 strains. In the course of an in vitro R5 infection, the delay of emergence of X4 mutants was similar between cells expressing 2 distinct cell surface CCR5 densities, but shorter (12 ± 0 days and 21 ± 0 days, respectively, P = 0.01) in cells expressing a high surface CXCR4 density as compared with cells with a low surface CXCR4 density. These data argue for a role of CXCR4 density, but not of CCR5 density, in the emergence of X4 strains. They are reassuring concerning the risk of inducing an R5 to X4 switch using CCR5 antagonists to treat HIV infection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20861743     DOI: 10.1097/QAI.0b013e3181f25bab

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  6 in total

1.  Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load.

Authors:  Victor G Kramer; Susan M Schader; Maureen Oliveira; Susan P Colby-Germinario; Daniel A Donahue; Diane N Singhroy; Randy Tressler; Richard D Sloan; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

2.  Virological response after short-term CCR5 antagonist exposure in HIV-infected patients: frequency of subjects with virological response and associated factors.

Authors:  Ezequiel Ruiz-Mateos; Alejandro González-Serna; Miguel Genebat; Kawthar Machmach; Francesc Vidal; Angeles Muñoz-Fernández; Sara Ferrando-Martinez; Manuel Leal
Journal:  Antimicrob Agents Chemother       Date:  2011-08-01       Impact factor: 5.191

3.  Association between HIV-1 tropism and CCR5 human haplotype E in a Caucasian population.

Authors:  Kristi Huik; Radko Avi; Helen Uibopuu; Merit Pauskar; Tõnu Margus; Tõnis Karki; Tõnu Krispin; Piret Kool; Kristi Rüütel; Ave Talu; Katri Abel-Ollo; Anneli Uusküla; Andrew Carrillo; Weijing He; Sunil K Ahuja; Irja Lutsar
Journal:  J Acquir Immune Defic Syndr       Date:  2014-07-01       Impact factor: 3.731

4.  CCR5 expression is elevated on endocervical CD4+ T cells in healthy postmenopausal women.

Authors:  Amie L Meditz; Kerrie L Moreau; Samantha MaWhinney; Wendolyn S Gozansky; Kelsey Melander; Wendy M Kohrt; Margaret E Wierman; Elizabeth Connick
Journal:  J Acquir Immune Defic Syndr       Date:  2012-03-01       Impact factor: 3.731

5.  CIB1 and CIB2 are HIV-1 helper factors involved in viral entry.

Authors:  Ana Godinho-Santos; Allan J Hance; João Gonçalves; Fabrizio Mammano
Journal:  Sci Rep       Date:  2016-08-04       Impact factor: 4.379

6.  Immune activation correlates with and predicts CXCR4 co-receptor tropism switch in HIV-1 infection.

Authors:  Bridgette J Connell; Lucas E Hermans; Annemarie M J Wensing; Ingrid Schellens; Pauline J Schipper; Petra M van Ham; Dorien T C M de Jong; Sigrid Otto; Tholakele Mathe; Robert Moraba; José A M Borghans; Maria A Papathanasopoulos; Zita Kruize; Francois W D Venter; Neeltje A Kootstra; Hugo Tempelman; Kiki Tesselaar; Monique Nijhuis
Journal:  Sci Rep       Date:  2020-09-28       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.